Weiwei Xu Joins Pharmerit2011-11-17 - We are very pleased to announce that Weiwei Xu is joining Pharmerit’s growing team. Weiwei joined Pharmerit in November 2011 and is employed as a research consultant at the Strategic Market Access Department.
Weiwei holds a Medical Doctor degree at Nanjing Medical University of China, and a M.Sc. degree in Health economics, Policy & Law at Erasmus University Rotterdam. She has diverse working experiences as a clinical doctor, a researcher, and a lecturer. Before joining Pharmerit she has been working at the Erasmus University Rotterdam as a scientific researcher, focusing on her PhD thesis with the title “The prospect of competition in China’s healthcare reform”. In this thesis, international experience of a competitive healthcare market, including that of the Netherlands, UK, and Russia, is examined; eleven theoretical pre-conditions of effective competition in a healthcare system are explained, four out of the eleven are studied against the current Chinese healthcare system. Weiwei expects to obtain her PhD degree in Health Economics & Policy at Erasmus University Rotterdam within half a year. ISPOR 2011 – Research presented bij Ben van Hout received “Best Podium Research Presentation Award”2011-11-16 - Congratulations to Ben van Hout for receiving a ISPOR Research Presentation Award for the research: “COMBINING DCE AND TTO INTO A SINGLE VALUE FUNCTION”, which was presented by Ben at the ISPOR 14th Annual European Congress on Monday, 7 november 2011 at the Hotel Auditorium inMadrid, Spain. Cathelijne Alleman Joins Pharmerit2011-11-01 - We are very pleased to announce that Cathelijne Alleman is joining the Pharmerit team as a Research Assistant. Cathelijne holds a MSc degree in Public Administration from the Radboud University Nijmegen and a MSc degree in Health Economics, Policy and Law received at the Erasmus University Rotterdam.The topic of her last master thesis was a cost calculation of treatment with a chemotherapeutic drug that is used for childhood acute lymphoblastic leukemia. During this period she also worked as a student-assistant at the Erasmus University. Cathelijne will be part of the Strategic Market Access department, where she will assist on several projects. Pharmerit is Certified Solution Provider for BaseCase® software2011-10-31 - Pharmerit is now a Certified Solution Provider for the BaseCase® Interactive software. BaseCase® Interactive is a software platform to present and distribute health economic evidence such as cost-effectiveness or Budget Impact models. By certifying, Pharmerit has shown to be able to develop user friendly dashboards with the BaseCase software. This expands our possibilities to create user friendly communication solutions for our clients. Craig Bennison joins Pharmerit2011-10-03 - We are very pleased to announce that Craig Bennison is joining the UK Pharmerit team as a Junior Research Consultant. Craig has just completed his MSc in Economics and Health Economics at the University of Sheffield. His thesis topic was re-estimating the SF-6d tariff using TTO. Craig's first projects will include assisting global models and systematic reviews Pharmerit's Bayesian meta-analysis of MRSA antibiotics in CMRO's Top 10 accessed and cited papers 20102011-10-03 - Pharmerit congratulates Jennifer Stephens PharmD, Bart Heeg MSc, and Prof. Ben van Hout PhD. with the study entitled “Comparative effectiveness of anitbiotics for the treatment of MRSA complicated skin and soft tissue infections1” being in the top 10 of Current Medical Research and Opinion (CMRO)'s accessed and cited papers for 2010.
Pharmerit's study "The burden of atrial fibrillation in the Netherlands" published2011-09-30 - Pharmerit is pleased to announce their paper with the title "The burden of atrial fibrillation in the Netherlands" is published in the Netherlands Heart Journal.
Atrial fibrillation (AF) is the most commen sustained atrial arrhythmia and it is independently associated with an increased morbidity and mortality. This study describes the economical and clinical impact of AF in the Netherlands. AF is a serious disease with a high clinical and economic burden, especially due to hospitalisations as a result of cardiovascular events. The number of patients with AF in the Netherlands is considerable and will increase with the ageing population in the future.
Netherlands Heart Journal Volume 19, Number 9, 373-378, DOI: 10.1007/s12471-011-0175-4 Two poster presentations at the 13th European AIDS conference in Belgrade, Serbia2011-09-21 - Pharmerit is pleased to announce that two of its studies on treatments for HIV-1 infected patients will be presented at the upcoming European AIDS conference in Begrade, Serbia (12 to 15 october 2011).
Mata Charokopou joins Pharmerit2011-09-05 - Mata Charokopou has joined Pharmerit’s team based in the Netherlands in the role of research assistant. Recently, Mata defended her MSc thesis on the price and efficacy of oncology drugs and received her Master of Science degree in Health Economics, Policy and Law from the Erasmus University of Rotterdam. During the last phase of her study Mata completed a research internship at Pharmerit.During this internship she was involved in the development of an in house database that includes information on HTA assessments and pricing and reimbursement status of a selection of recently approved medicinal products on the EU market. Mata also received her Master of Science degree in Pharmacy from the University of Patras, Greece, in 2010. Mata will familiarize with the aspects of health economic research and she will contribute to projects by conducting literature reviews and aiding with data analysis and model development. Sonam Mehta joins Pharmerit 2011-09-20 - We are very pleased to announce that Sonam Mehta is joining the Pharmerit team as Outcomes Research Analyst. Sonam graduated this summer with a Master of Science in Pharmacy Administration from the Univeristy of Houston. Her thesis topic was comparative effectiveness of mood-stabilizers vs atypical antipsychotics in children & adolescents with biploar disorder using Medicaid claims data.Sonam's first projects will include assisting with the pain meta-analysis and several chart review/survey studies. Istvan Majer joins Pharmerit2011-09-20 - We are very pleased to announce that Istvan Majer is joining Pharmerit's growing team. He will we be part of the European HEOR team. Istvan is about to finish his Ph.D on modeling disability and mortality at the Erasmus Medical Centre. During his Ph.D he used econometric and (bio-) statistical models to predict and forecast healthy life expectancy and overall life expectancy, an important topic in our ageing societies. He received his M.Sc degree in Health economics at the Erasmus University. Before his study Pharmerit cost-effectiveness analysis of ticagrelor positively reviewed by CVZ2011-08-29 - The Medicinal Products Reimbursement Committee (CFH) has reviewed the pharmaco-economic submission by the manufacturer of ticagrelor (Brilique®). The CFH concluded that the cost-effectiveness of ticagrelor has been substantiated. Based on the clinical and health economic evidence provided the CFH recommends that ticagrelor should be reimbursed in the Netherlands. Staff Contributions to ISPOR 14th Annual EU congress, Madrid2011-08-17 - Pharmerit is pleased to announce that our staff is contributing to two podium presentations, one workshop, and a total of nineteen poster presentations Marieke Heisen joins Pharmerit.2011-05-09 - We are delighted to welcome Marieke to our European team. Marieke brings her experience of medical devices and biomedical engineering to our expanding HEOR group. Before joining Pharmerit, Marieke conducted a PhD in pharmacokinetic analysis of dynamic contrast enhanced (DCE) MRI data of the breast, to detect and characterize cancer. Her PhD built up on her Masters project which was conducted in a collaboration between the Biomedical Image Analysis group at Eindhoven University of Technology and the Clinical Science & Advanced Development group at Philips Healthcare in Best. Marieke joined Pharmerit in May 2011 and is currently employed as Research Consultant Health Economics & Outcomes Research. Cagdas Buyukkaramikli joins Pharmerit.2011-05-09 - We are very pleased to announce that Cagdas joins our European HEOR team. Cagdas brings his experience in discrete event simulation and stochastic modeling and optimization. Cagdas received his M Sc. Degree in Industrial Engineering & Operations Research from Bilkent University. He is defending his PhD thesis this year, on the optimal integrated capacity and availability management of maintenance repair systems. Next to his academic background, he was involved in many projects in the industry. Cagdas joined Pharmerit in June 2011 and is currently employed as Research Consultant Health Economics & Outcomes Research. Poster presentation at EULAR2011-05-27 - Pharmerit International is pleased to report that its study “Impact of Age at Therapy Initiation on the Cost Effectiveness of Adalimumab in Ankylosing Spondylitis”has been selected for a poster presentation at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology on the 27 of May 2011, in London. Pharmerit to present several economic studies at ASCO2011-05-20 - Pharmerit is pleased to announce that our staff will be presenting a total of four studies (of which three are formal cost effectiveness analyses and one is a modeling exercise to estimate survival in leukemia) assessing the costs and benefits of various oncology treatments at the upcoming 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, USA (June 3-7, 2011).
Pharmerit Researcher Ning Yan Gu, PhD publishes study on infected total hip arthroplasty2011-05-09 - Ning Yan Gu, PhD, modeled and co-authored a decision analysis study entitled “comparison of one and two-stage revision of total hip arthroplasty complicated by infection: a Markov expected-utility decision analysis“ recently published in the premier orthopedic journal, the Journal of Bone and Joint Surgery (view article). The study was conducted based on a collaborative effort/interest between a group of health economists (Dr. Ning Yan Gu at Pharmerit and Dr. Jason Doctor at University of Southern California) and orthopedic surgeons (Dr. Chris Wolf, Dr. Paul Manner and Dr. Seth Leopold at University of Washington). The current publication investigated and compared the impact of a traditional two-stage surgical procedure with a one-stage direct exchange arthroplasty on quality-of-life (QoL) of patients with infected total hip arthroplasty, evaluated from both patient and surgeon perspectives. Findings from the study favored one-stage over two-staged revision approach after taking patients’ QoL into consideration. Leading orthopedic surgeons have commented that “this study should be considered hypothesis-generating for future randomized controlled trials in which, ideally, health end points will be considered in addition to the eradication of infection” (1) (2). Dr. Gu and colleagues were also invited to a featured question interview from Orthopedic Today (forthcoming) about the study and, a paper presentation will be made at a 63th Annual Meeting of the Association of Bone and Joint Surgeons at Dublin, Ireland in June 2011. This latest study builds upon an earlier research project published in Value in Health by Dr. Gu and colleagues entitled “A comparison of physician and patient time tradeoffs for postoperative hip outcomes” (view article). In this project, the authors elicited patient’s and surgeon’s health preferences between shorter survival times in good health or longer survival times in various levels of poor health. Physicians were questioned on the decisions they were making for their patients. Result suggested that physicians were somewhat more willing to accept reduced lifespan with a better quality of life than were patients. The article related news release can be found at: ispor.org and medicalnewstoday.com Pharmerit congratulates Dipen Patel, PhD, on the publication of his study on economic burden of food allergies06-05-2011 - Dipen Patel, PhD, is the leading author of a study entitled “Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States“ published in the premier allergy journal, Journal of Allergy and Clinical Immunology. (view article). The study was funded by Food Allergy and Anaphylaxis Network and served as Dr. Patel’s PhD dissertation. Using several databases, Patel and colleagues David Holdford, PhD, Eric Edwards, BS, NV Carroll, PhD from the Virginia Commonwealth University in Richmond, tallied the cost of emergency room care, hospitalizations, and visits to the physician's office for food allergic reactions. These numbers were used to estimate the nationwide cost of treatment. Indirect costs were also quantified by estimating lost productivity in terms of lost earnings caused by absenteeism and mortality of patients or caregivers. Thorough sensitivity analyses were conducted to measure robustness of the estimates. The researchers found that the economic burden of food allergic and anaphylactic reactions was an estimated half a billion dollars in 2007. Ambulatory visits accounted for more than half of the costs. The study has been picked up in the national media (1) (2) (3), including being aired on CNN’s HLN news on the morning of May 6, 2011. Budget Impact Modelling Workshop at the Annual Academy of Managed Care Pharmacy (AMCP) Meeting in Minneapolis, MN USA.2011-05-02 - Pharmerit staff Sonya Snedecor and Phillip Wiegand, along with Joel Hay, professor and founding chair of the department of Pharmaceutical Economics and Policy at the School of Pharmacy at the University of Southern California, and Prabashni Reddy, director of the Center for Drug Policy (CDP) at Partners Healthcare, delivered the session “Budget Impact Models in MCO Decision Making: Current Practice, Challenges and Insights” to attendees of the annual AMCP conference in Minneapolis, MN on April 29th, 2011. The session described the basics of budget impact modelling, addressed important considerations around model inputs and provided a practical example demonstrating how budget impact models have to be created and modified to meet the needs of a hospital consortium in the United States. A link to the presentation can be found here. Lavanya Reddy Sudharshan joins Pharmerit2011-04-25 - Pharmerit International is pleased to announce that Lavanya Reddy Sudharshan has joined its rapidly growing team. Ms Sudharashan will be a Senior Outcomes Research Analyst in our Bethesda, MD office. “We are very delighted to welcome Lavanya to our team”, said Marc Botteman, Managing Partner of Pharmerit in North America. “Lavanya brings several years of consulting experience to our continuously expanding group of market access, policy, and health economics and outcomes research experts.” Before joining Pharmerit, Lavanya worked for several years as a research associate in a contract research organization where she executed and interpreted the analysis of health services research, outcomes research, and economic evaluations for several pharmaceutical drug and device companies. Her experience included development of global value dossiers and AMCP dossiers, literature reviews, and creation of value messages to support product positioning, enabling clients to better prepare for product launch. In addition, her market access experience includes conduct of stakeholder interviews to understand reimbursement, pricing and policy issues related to drugs/devices, providing clients strategic recommendations for market uptake. Her data analysis and modeling experience included budget impact and burden of illness studies, using national survey databases including Medicaid and Medicare to determine utilization patterns of various products. Prior to that she was a Research Assistant at Department of Clinical Sciences and Administration, University of Houston, Texas, where she earned a Master of Science in Pharmacy Administration. Pharmerit presents at Market Access congress, Berlin2011-03-15 - Pharmerit is pleased to announce that Harald Heemstra presented "Pricing and reimbursement of pharmaceuticals in Germany - What lessons can be learned from abroad?" at the Congress "Pharmaceutical & Medical Device Market Access in Germany after Major Pricing & Reimbursement", on the 15th of March in the Marriott Hotel, Berlin (Germany). Izabela Kucmin-Bemelmans joins Pharmerit.2011-03-09 - “We are delighted to welcome Izabela to our team”, said Lex Tergau, Managing Partner of Pharmerit in Europe. “Izabela brings her experience of the Central and Eastern European healthcare landscape to our expanding group of market access and policy researchers.” Before joining Pharmerit, Izabela was responsible for developing and implementing marketing and communication strategies as a key account manager at Arcana Institute, a healthcare consultancy company based in Krakow, Poland. Prior to that Izabela worked at the National Institute of Public Health in Warsaw, Poland. Izabela received a Master of Science degree in Public Health from the Collegium Medicum Jagiellonian University, Krakow, Poland, and an MSc degree in Public Health from the University of Maastricht, The Netherlands. She obtained a postgraduate diploma in Marketing from the Krakow School of Business. Click here to view Izabela Kucmin’s profile. ISPOR 16th Annual International Meeting2011-03-08 - Pharmerit is pleased to announce that its workshop, "Application and use of dynamic models in health economic analyses" has been selected for presentation at the ISPOR 16th Annual International Meeting. We are pleased to present this in collaboration with Elamin Elbasha and Erik Dasbach of Merck and Co. ISPOR 16th Annual International Meeting2011-03-07 - Pharmerit is pleased to announce that its abstract entitled 'Updated economic analysis of fesoterodine relative to tolterodine and solifenacin for the treatment of overactive bladder: the swedish perspective' has been accepted for presentation at the ISPOR 16th Annual International Meeting New employees2011-02-10 - Kirsten Westerhout, PharmD, has recently joined Pharmerit ’s team based in the Netherlands in the role of Junior Research Consultant. Kirsten received her Master of Science degree in Pharmacy from the University of Utrecht. During the last phase of her studies she completed a research internship at Pharmerit. “We were very impressed by Kirsten’s analytical skills and the ease with which she familiarized herself with the aspects of health economic research”, said Bart Heeg, Director of Health Economics & Outcomes Research. “With her mathematical mind and Pharmacy background, Kirsten has what it takes to be an excellent researcher in this field.” Click here to view Kirsten Westerhout’s profile. Michael Tempest, has recently joined Pharmerit’s team based in the UK in the role of research assistant. Michael received his Bachelor of Science degree in Pharmacology from the University of Leeds. “Having been trained in Pharmacology, Michael’s skills very nicely complement the skills of our multidisciplinary team in York”, said Stephanie Thurston, Senior Research Consultant Health Economics & Outcomes Research. Michael will contribute to projects by conducting literature reviews and aiding with data analysis and model development. Click here to view Michael Tempest’s profile. 6th congress of ECCO2011-01-03 - Pharmerit is pleased to announce that its research in ulcerative colitis (UC) has been accepted for presentation at the 6th Congress of ECCO; Inflammatory Bowel Diseases 2011, February 24-26, 2011 in Dublin/Ireland. This health economic analysis estimates the cost and effects of treating patients with acute exacerbations in UC in the Netherlands.
|